Table 8.

Immune-modulators in clinical trials for HCC treatment

S. No.	Drug	Molecular targets	Phases of clinical trial	Year and references
1	Tremelimumab	CTLA-4	II	2013 [141]
2	Icaritin	IL-6/Jak2/Stat3	II	2015 [142]
3	Lenalidomide	TNF-α, interferon γ, IL-6, IL-10, and IL-12.	II	2015 [143]
4	Codrituzumab	Glypican-3	II	2016 [144]
5	Nivolumab	PD-1	I	2016 [145]
6	Ipilimumab	CTLA-4	II	2017 [146]
7	Tasquinimod	Protein S100A9	II	2017 [147]